Forest Laboratories, Inc. and Nycomed Announce a Conference Call to Review Publication of Daxas Phase III Clinical Trial Results
NEW YORK--(BUSINESS WIRE)--Aug 27, 2009 - Forest Laboratories, Inc. (NYSE: FRX), an international manufacturer and marketer of pharmaceutical products and Nycomed, a privately owned pharmaceutical company, will host a conference call at 7:15 AM EDT on Friday, August 28, 2009. Dr. Lawrence Olanoff, President and Chief Operating Officer of Forest Labs, Dr. Marco Taglietti, President of Forest Research Institute, Dr. Anders Ullman, Executive Vice President R&D of Nycomed and Professor Fernando Martinez from the University of Michigan will discuss the results of the Daxas® Phase III clinical trials that were published in The Lancet today.
The conference call will be webcast live beginning at 7:15 AM EDT on the Company's website www.frx.com and also on the website www.streetevents.com. Please log on to either website at least fifteen minutes prior to the conference call as it may be necessary to download software to access the call. A replay of the conference call will be available until September 11, 2009 at both websites and also by dialing 1-800-642-1687 (US investors) or +1-706-645-9291 (international investors), Conference Call ID 27580393.
Nycomed is a privately owned global pharmaceutical company with a differentiated portfolio focused on branded medicines in gastroenterology, respiratory and inflammatory diseases, pain, osteoporosis and tissue management. An extensive range of OTC products completes the portfolio. Its R&D is structured around partnerships and in-licensing is a cornerstone of the company's growth strategy.
Nycomed employs 12,000 associates worldwide, and its products are available in more than 100 countries. It has strong platforms in Europe and in fast-growing markets such as Russia/CIS and Latin America. While the US and Japan are commercialized through best-in-class partners, Nycomed plans to further strengthen its own position in key Asian markets.
Headquartered in Zurich, Switzerland, the company generated total sales of ‚¬3.4 billion in 2008 and an adjusted EBITDA of ‚¬1.2 billion. For more information visit www.nycomed.com.
|General phone: +41 44 555 15 10|
|Beatrix Benz, phone: +41 79 218 9824|
|Tobias Cottmann, phone: +41 44 555 15 01|
|Christian B. Seidelin, phone: +41 44 555 11 04|
Forest Laboratories (NYSE: FRX) is a U.S.-based pharmaceutical company with a long track record of building partnerships and developing and marketing products that make a positive difference in people's lives. In addition to its well-established franchises in therapeutic areas of the central nervous and cardiovascular systems, Forest's current pipeline includes product candidates in all stages of development and across a wide range of therapeutic areas. The company is headquartered in New York, NY. To learn more about Forest Laboratories, visit www.frx.com.
Except for the historical information contained herein, this release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements involve a number of risks and uncertainties, including the difficulty of predicting FDA approvals, the acceptance and demand for new pharmaceutical products, the impact of competitive products and pricing, the timely development and launch of new products, and the risk factors listed from time to time in Forest Laboratories' Annual Report on Form 10-K, Quarterly Report on Form 10-Q, and any subsequent SEC filings.
Contact: Forest Laboratories, Inc.
Frank J. Murdolo, 1-212-224-6714
Vice President - Investor Relations
Posted: August 2009